

## PROLIGHT DIAGNOSTICS PUBLISHES INVESTOR LETTER FOR AUGUST 2025

The investor letter notes, among other things, that all potential partners we met during the ADLM congress were highly impressed by Psyros' performance, with its ability to deliver high sensitivity results combined with its sleek compact look, intelligent features and very competitively priced consumable cartridge.

The investor letter is available via the attached file or on the company's website: <https://prolightdx.com/en/mediaeng/investor-letters/>

### For further information, please contact:

Ulf Bladin, CEO

E-mail: [info@prolightdx.com](mailto:info@prolightdx.com)

Phone: +46 73 582 39 87

Company website: [www.prolightdx.com](http://www.prolightdx.com)

### About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

### Attachments

**Prolight Diagnostics - Investor letter August 1 2025**

**Prolight Diagnostics publishes investor letter for August 2025**